Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim(®)) in the treatment of uncomplicated malaria at public health facilities in four African countries.

Malaria Journal
Alexander AdjeiMargaret Gyapong

Abstract

Dihydroartemisinin-piperaquine (DHA-PQ) is one of five WHO recommended artemisinin combination therapy (ACT) for the treatment of uncomplicated malaria. However, little was known on its post-registration safety and effectiveness in sub-Saharan Africa. DHA-PQ provides a long post-treatment prophylactic effect against re-infection; however, new infections have been reported within a few weeks of treatment, especially in children. This paper reports the clinical outcomes following administration of DHQ-PQ in real-life conditions in public health facilities in Burkina Faso, Ghana, Mozambique, and Tanzania for the treatment of confirmed uncomplicated malaria. An observational, non-comparative, longitudinal study was conducted on 10,591 patients with confirmed uncomplicated malaria visiting public health facilities within seven health and demographic surveillance system sites in four African countries (Ghana, Tanzania, Burkina Faso, Mozambique) between September 2013 and April 2014. Patients were treated with DHA-PQ based on body weight and followed up for 28 days to assess the clinical outcome. A nested cohort of 1002 was intensely followed up. Clinical outcome was assessed using the proportion of patients who reported signs and sym...Continue Reading

References

Jun 13, 2006·Transactions of the Royal Society of Tropical Medicine and Hygiene·Corine KaremaUmberto D'Alessandro
Jul 31, 2007·Transactions of the Royal Society of Tropical Medicine and Hygiene·H Y MyintN J White
Nov 9, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Issaka ZongoJean Bosco Ouédraogo
Aug 21, 2009·Malaria Journal·Kasia StepniewskaJean-René Kiechel
Oct 7, 2011·The American Journal of Tropical Medicine and Hygiene·Piero OlliaroJulien Zwang
Aug 11, 2012·Malaria Journal·Simon L CroftHan-Jong Rim
Aug 31, 2012·International Journal of Epidemiology·Abraham Rexford OduroFred Binka
Oct 10, 2012·International Journal of Epidemiology·Karim DerraHalidou Tinto
Oct 26, 2013·International Journal of Epidemiology·Charfudin SacoorTacilta Nhampossa
Dec 7, 2013·PLoS Medicine·UNKNOWN WorldWide Antimalarial Resistance Network (WWARN) DP Study Group
Jan 15, 2014·International Journal of Epidemiology·Margaret GyapongFred N Binka
Mar 10, 2015·International Journal of Epidemiology·Sigilbert MremaHonorati Masanja

❮ Previous
Next ❯

Citations

Nov 21, 2016·The Lancet Infectious Diseases·Quique Bassat, Clara Menéndez
May 4, 2018·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Alexander N O Dodoo
Sep 29, 2020·Journal of Pharmaceutical Sciences·Kouadio Victorien KonanMircea Alexandru Mateescu

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02199951

Software Mentioned

STATA
Open Clinica

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.